Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, ZepboundCNBC • 12/18/25
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trialPRNewsWire • 12/18/25
Eli Lilly cuts price of diabetes, weight-loss drugs in Canada, Globe and Mail reportsReuters • 12/18/25
Eli Lilly's stock has crushed Nvidia's in recent weeks. What history has to say about that.Market Watch • 12/17/25
Billionaire With 30 Years of 30% CAGR Gains Dumped Nvidia, Palantir, and Eli Lilly24/7 Wall Street • 12/17/25
Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America SaysBenzinga • 12/15/25
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III WinZacks Investment Research • 12/12/25
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancerPRNewsWire • 12/12/25
Eli Lilly Rises, Again, After EMA Recommends Mounjaro For Children As Young As 10Investors Business Daily • 12/12/25
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Dec 2025)24/7 Wall Street • 12/12/25